Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performan...
Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal...
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI) for its lead asset, AVLAYAH™ (tividenofusp alfa-eknm). This represents more than just a new treatment for Hunter Syndrome; it marks the first time in medical history that [...]
Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately
as healthcare stocks have returned 10.8% over the past six months, topping the S&P 500 by 4.1 percentage points.
Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key royalty streams and a limited contribution from recent acquisitions. CEO Pablo Legorreta pointed to the diversification and resilience of the portfolio as a mitigating factor, emphasizing that “conversion of CF patients to new therapies has been steady but gradual.” Management also noted that increased capital deployment in late 2025 was balanced by a disciplined approach to share repurchases, reflecting a flexible capital allocation framework.
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per share was 57.3% below analysts’ consensus estimates.
